Medicare Compliance & Reimbursement

82% of whistleblowers in NEJM study were subjected to pressures by their company. When Congress passed the healthcare bill in March 2010, everyone said that there was an even greater need for whistleblowers to identify fraud in the healthcare industry. But with the passage of a few months now, it looks like these whistleblowers are getting a raw deal. A blog post on www.quitamteam.com mentions a New England Journal of Medicine (NEJM) study entitled, "Whistle-blowers' experiences in fraud litigation against pharmaceutical companies." The study, it says, confirms what was already common knowledge: whistleblowers who report healthcare fraud receive little support and experience substantial stress. The findings of this study appear to confirm what other studies have revealed in the past, that pharmaceutical whistleblowers "just don't get any respect." Whistleblower Intent Isn't Monetary In the NEJM study, the experiences of 42 pharmaceutical whistleblowers were examined and all but six of the [...]